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ABSTRACT When it is difficult to develop selective
ligands within a family of related G-protein-coupled re-
ceptors (GPCRs), chemically engineered receptors acti-
vated solely by synthetic ligands (RASSLs) are useful
alternatives for probing receptor function. In the present
work, we explored whether a RASSL of the free fatty acid
receptor 2 (FFA2) could be developed on the basis of
pharmacological variation between species orthologs. For
this, bovine FFA2 was characterized, revealing distinct
ligand selectivity compared with human FFA2. Homology
modeling and mutational analysis demonstrated a single
mutation in human FFA2 of C4.57G resulted in a human
FFA2 receptor with ligand selectivity similar to the bovine
receptor. This was exploited to generate human FFA2-
RASSL by the addition of a second mutation at a known
orthosteric ligand interaction site, H6.55Q. The resulting
FFA2-RASSL displayed a >100-fold loss of activity to
endogenous ligands, while responding to the distinct
ligand sorbic acid with pEC50 values for inhibition of
cAMP, 5.83  0.11; Ca2 mobilization, 4.63  0.05; ERK
phosphorylation, 5.61  0.06; and dynamic mass redistri-
bution, 5.35  0.06. This FFA2-RASSL will be useful in
future studies on this receptor and demonstrates that
exploitation of pharmacological variation between species
orthologs is a powerful method to generate novel chemi-
cally engineered GPCRs.—Hudson, B. D., Christiansen,
E., Tikhonova, I. G., Grundmann, M., Kostenis, E., Ad-
ams, D. R., Ulven, T., Milligan, G. Chemically engineering
ligand selectivity at the free fatty acid receptor 2 based on
pharmacological variation between species orthologs.
FASEB J. 26, 4951–4965 (2012). www.fasebj.org
Key Words: GPCR  RASSL
In recent times, it has become apparent that a series
of molecules previously considered only as metabolic
intermediates are actually able to mediate at least a
number of their functions via activation of members of
the G-protein-coupled receptor (GPCR) superfamily.
These include intermediates of the tricarboxylic acid
cycle, such as succinate (1), and molecules such as
lactate (2) and -hydroxybutyrate (3), involved in glu-
cogenic and ketogenic control of metabolism. A further
group of such intermediates are the free fatty acids. It is
now known that three related GPCRs, free fatty acid
receptors 1–3 (FFA1, FFA2, and FFA3; previously des-
ignated GPR40, GPR43, and GPR41, respectively;
ref. 4), respond to either medium- and longer-chain
(FFA1) or short-chain, C1-C5, (FFA2 and FFA3) free
fatty acids. There is considerable interest in the physi-
ological roles of FFA2, in particular (5, 6), and whether
this receptor might be useful as a novel therapeutic
target in areas ranging from diabetes and adiposity to
satiety and inflammation (7, 8). In the absence of
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synthetic ligands that bind to the same region of the
receptor as the short-chain fatty acids (SCFAs) and that
have reasonable potency and substantial selectivity be-
tween FFA2 and FFA3, the marked overlap of potency
of C1–C5 fatty acids at FFA2 and FFA3 makes efforts to
interpret selective activation of FFA2 vs. FFA3 imprac-
tical without more detailed analyses involving knockout
or knockdown studies (9–11). It would, therefore, be of
considerable value to develop chemically engineered
forms of these receptors with unique ligand responsive-
ness.
Such modified GPCRs have been developed for
several other receptors and are often described as
either designer receptors exclusively activated by de-
signed drugs (DREADDs) or as receptors activated
solely by synthetic ligands (RASSLs) (12–15). To date,
two general approaches have been employed to gener-
ate these chemically engineered GPCRs (16). The first
involves site-directed mutagenesis of known ligand in-
teraction sites in the GPCR followed by screening
ligands for activity at the resulting mutant receptors
(17), while the second method takes the opposite
approach, generating thousands of randomly mutated
forms of the receptor and screening these against a
candidate synthetic ligand (13). Although each of these
approaches has found some success, both rely largely
on random screening. Considering this, in the present
work, we have explored whether a more direct ap-
proach could be taken to develop chemically engi-
neered forms of human FFA2 (hFFA2), based on the
variation between species orthologs of this receptor.
Mammalian species orthologs of GPCRs are antici-
pated to respond to the same endogenously produced
agonists. However, the potency and affinity of such
agonist ligands may vary depending on the physiology
of individual species, and where such receptors re-
spond to a number of related ligands (as in the case of
FFA2 and the SCFAs; refs. 4, 18), the rank order of
function may differ. Although such variation is likely to
be limited for GPCRs that coordinate the responses of
ancient hormone and transmitter systems, such as the
catecholamines, that underpin key physiological pro-
cesses, including heart rate and intraneural communi-
cation, such differences may be substantially greater for
GPCRs that play more modulatory roles, or in cases
where the receptor is likely to be exposed to vastly
different concentrations of ligand between different
species. Because SCFAs are primarily produced by the
fermentation of nondigestible carbohydrates by the
microflora in the gut (6), it could be hypothesized that
FFA2 will show significant ortholog variation between
species that have greatly different dietary levels of
nondigestible carbohydrates and, therefore, different
levels of endogenous SCFA ligands. Considering this, in
the present work, the bovine ortholog was chosen as the
basis for producing chemically engineered forms of
hFFA2, since ruminants, such as bovines, are well
known to rely heavily on nondigestible carbohydrates.
MATERIALS AND METHODS
Cell culture, transfection, and production of stably
expressing cell lines
HEK293 cells were maintained in Dulbecco’s modified Ea-
gle’s medium (DMEM) supplemented with 10% FBS at 37°C
and 5% CO2. For experiments utilizing transiently transfected
HEK293 cells, transfections were carried out using polyethyl-
enimine, and experiments were conducted 48 h post-trans-
fection. For experiments in which stable cell lines were
produced and used, the Flp-In T-REx system (Life Technol-
ogies, Paisley, UK) was used to generate HEK293 cells with
tetracycline-inducible expression of the receptor of interest.
To generate these cell lines, Flp-In T-REx HEK293 cells were
cotransfected with the pOG44 vector and the receptor of
interest in pcDNA5/FRT/TO. Transfection with pOG44
drives expression of Flp recombinase, which, in turn, allows
for recombination between FRT sites in pcDNA5/FRT/TO
and in the genome of the Flp-In T-REx HEK293 cells, thus
allowing stable inducible cells for the receptor of interest to
be generated by appropriate antibiotic selection.
DNA constructs
Constructs for the human orthologs of FFA2 and FFA3 fused
at their C-terminal with enhanced yellow fluorescent protein
(eYFP) were as reported previously (19). To clone the bovine
orthologs, the coding sequences of bovine FFA2 and FFA3
(bFFA2 and bFFA3) were amplified without their stop codons
from commercially available bovine genomic DNA by PCR.
The PCR product was then ligated upstream and in-frame
with the eYFP sequence present in a pcDNA5/FRT/TO
expression vector (Life Technologies, Carlsbad, CA, USA).
Mutagenesis of human and bovine orthologs of FFA2 was
carried out according to the QuickChange method (Strat-
agene, Santa Clara, CA, USA).
Compounds
Formic acid (compound C1), acetic acid (compound C2),
propionic acid (compound C3), butyric acid (compound C4),
valeric acid (compound C5), caproic acid (compound C6),
heptanoic acid (compound C7), caprylic acid (compound C8),
pelargonic acid (compound C9), methylthioacetic acid (com-
pound 1), 3-methylbutyric acid (compound 2), pivalic acid
(compound 3), 2-methylbutyric acid (compound 4), cyclopro-
pylcarboxylic acid (compound 5), cyclobutylcarboxylic acid
(compound 6), 1-methylcyclopropanecarboxylic acid (com-
pound 7), vinylacetic acid (compound 9), 3-pentenoic acid
(compound 12), acrylic acid (compound 13), propiolic acid
(compound 14), 2-butynoic acid (compound 15), trans-crotonic
acid (compound 16), 2-methylacrylic acid (compound 18),
3-methylcrotonic acid (compound 19), trans-2-methylcrotonic
acid (compound 20), trans-2-pentenoic acid (compound 22),
trans-2-hexenoic acid (compound 23), 2,4-pentadienoic acid
(compound 24), sorbic acid (compound 25), 4,4,4-trifluoro-3-
methyl-2-butenoic acid (compound 26), 1-cyclopentenecarboxy-
lic acid (compound 27), trans-cinnamic acid (compound 28),
and 1-cyclohexene-1-carboxylic acid (compound 29) were all
purchased from Sigma-Aldrich (Dorset, UK). Angelic acid (com-
pound 21) was obtained from ABCR (Karlsruhe, Germany).
Cyclopropylacetic acid (compound 8) was purchased from
Alfa Aesar (Heysham, UK). 3-Butynoic acid (compound
10) was synthesized as described previously (20). The
identity and purity of all compounds were confirmed by 1H
and 13C NMR.
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-Arrestin-2 interaction assay
A bioluminescence resonance energy transfer (BRET)-based
approach was used to measure -arrestin-2 recruitment to
human and bovine forms of FFA2. Briefly, a plasmid encod-
ing an eYFP-tagged form of the receptor to be assayed was
cotransfected in a 4:1 ratio with a -arrestin-2 Renilla lu-
ciferase (Rluc) plasmid. Cells were transferred into white
96-well plates at 24 h post-transfection. Then, at 48 h post-
transfection, cells were washed, and the culture medium was
replaced with Hanks’ balanced salt solution (HBSS) immedi-
ately prior to conducting the assay. To measure -arrestin-2
recruitment, the Rluc substrate coelenterazine h was added to
a final concentration of 5 M; then, cells were incubated for
10 min at 37°C, test compounds were next added, and cells
were incubated for a further 5 min at 37°C. BRET, resulting
from FFA2 receptor--arrestin-2 interaction, was then as-
sessed by measuring the ratio of luminescence at 535 and 475
nm using a Pherastar FS fitted with the BRET1 optic module
(BMG Labtech, Aylesbury, UK).
Extracellular signal-regulated kinase (ERK) 1/2
phosphorylation assay
All ERK phosphorylation experiments were carried out using
Flp-In T-REx stable-inducible cell lines for the human or
bovine forms of FFA2 to be assayed. Briefly, 80,000 cells/well
were seeded in a 96-well plate and then allowed to attach for
3–6 h before the addition of doxycycline (100 ng/ml) to
induce expression of the receptor. After incubating over-
night, the culture medium was replaced with serum-free
DMEM-containing doxycycline (100 ng/ml), and cells were
then incubated for a further 5 or 6 h prior to the assay. For
the assay, test compounds were added to the cells and
incubated at 37°C for 5 min before the cells were lysed and
assayed for phospho-ERK using an Alphascreen-based detec-
tion kit (Perkin Elmer, Waltham, MA, USA), according to the
manufacturer’s protocol.
Ca2 mobilization assay
All Ca2 experiments were carried out using Flp-In T-REx
stable-inducible cell lines for the human or bovine forms of
FFA2 to be studied. Cells were plated at 80,000 cells/well in
black 96-well plates with clear bottoms and then allowed to
adhere for 3–6 h. Doxycycline was then added (100 ng/ml)
to induce expression of the receptor of interest, and cells
were maintained in culture overnight. Prior to the assay, cells
were labeled for 45 min with the calcium-sensitive dye Fura-2
AM; then they were washed and maintained in HBSS. Fura-2
fluorescent emission at 510 nm resulting from 340- or 380-nm
excitation was then monitored using a Flexstation plate
reader (Molecular Devices, Sunnyvale, CA, USA). Basal fluo-
rescence was measured for 16 s, test compounds were then
added, and fluorescence was measured for an additional 74 s.
The maximum difference in 340/380 ratios obtained before
and after compound addition was then used to plot concen-
tration-response data.
cAMP assay
All cAMP experiments were carried out using Flp-In T-REx
stable-inducible cell lines for the forms of FFA2 to be studied.
These experiments were carried out using a homogenous
time-resolved FRET-based detection kit (CisBio Bioassays;
CisBio, Codolet, France) according to the manufacturer’s
protocol. Cells were plated at 2000 cells/well in low-volume
384-well plates, and the inhibition of 1 M forskolin-stimu-
lated cAMP production was assessed following a 30-min
coincubation with test compounds.
[35S]GTPS incorporation assay
Total cell membranes were prepared from stable, doxycyline-
inducible Flp-In T-REx HEK293 cell lines. [35S]GTPS bind-
ing assays were then carried out in reactions with 5 g of cell
membrane protein preincubated for 15 min at 25°C in assay
buffer (50 mM Tris-HCl, pH 7.4; 10 mM MgCl2; 100 mM
NaCl; 1 mM EDTA; 1 M GDP; and 0.5% fatty acid-free BSA)
containing the indicated concentrations of ligands. The reac-
tion was initiated with the addition of 50 nCi of [35S]GTPS
to each tube, and the reaction was terminated after 1 h
incubation by rapid filtration through GF/C glass filters.
Unbound radioligand was washed from filters by 3 washes
with ice-cold wash buffer (50 mM Tris-HCl, pH 7.4, and 10
mM MgCl2), and [
35S]GTPS binding was determined by
liquid scintillation spectrometry.
Homology modeling
Modeling of hFFA2 was carried out using the 2-adrenergic
receptor structure as a template (20, 21). The bFFA2 homol-
ogy model was constructed on the basis of this hFFA2 model
using the Prime module of Schrödinger software with default
options (Schrödinger LLC, New York, NY, USA).
Dynamic mass redistribution (DMR) assays
DMR assays were performed on a beta version of the Corning
Epic biosensor (Corning Life Sciences, Corning, NY, USA), as
described previously in detail (22, 23). Briefly, stable induc-
ible cell lines expressing the hFFA2 or hFFA2-C4.57G/
H6.55Q mutant were grown to confluence for 20–24 h on
fibronectin-coated Epic biosensor 384-well microplates. Cells
were then washed twice with HBSS containing 20 mM HEPES
and kept for 1 h in the Epic reader at 28°C. DMR was
monitored before (baseline read) and after the addition of
compound solutions for6000 s. Concentration-effect curves
were generated from the real-time optical traces using the
area under the curve between 0 and 6000 s after ligand
addition.
Curve fitting and statistical analysis
All data presented represent means  se of 3 independent
experiments. Data analysis and curve fitting were carried out
using the GraphPad Prism 5.0b software package (GraphPad,
San Diego, CA, USA). Concentration-response data were fit to
3-parameter sigmoidal concentration-response curves. Statis-
tical analysis of curve fit parameters was carried out by
independently fitting the data from triplicate experiments
and comparing the resulting curve fit values by t test or 1-way
ANOVA, as appropriate.
RESULTS
Postactivation assays were established for both the
human and bovine orthologs of FFA2. In the first of
these, an ortholog of FFA2 to which eYFP had been
attached in-frame to the C terminus was cotransfected
into HEK 293 cells along with -arrestin-2 C-terminally
modified by the in-frame addition of Rluc. BRET
generated between Rluc and eYFP in response to an
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agonist ligand reflects induced interactions between
FFA2 and -arrestin-2. As anticipated from previous
studies using a number of different endpoints (19–21),
the SCFAs acetic acid (chain length C2) and propionic
acid (C3) displayed modest and similar potency at
hFFA2 in this assay (Fig. 1A). Although active at hFFA2,
n-butanoic acid (C4) displayed lower potency (Fig. 1A),
while both formic acid (C1) and valeric acid (C5) had
little effect at concentrations below 10 mM (Fig. 1A).
When equivalent studies were performed using bFFA2-
eYFP, a substantially different structure-activity relation-
ship (SAR) was observed. C1 was without effect, while
C2 was significantly (P0.05) less potent than com-
pound C3 (Fig. 1B). Furthermore, when exploring the
activity of fatty acids of longer chain length than C3,
potency significantly increased (P0.05), such that C3 
C4 C5 (Fig. 1B). Because of the increasing potency of
n-fatty acids with longer chain lengths observed at
bFFA2, we examined extended chain lengths from C6
to C9 at both the human and bovine forms of the
receptor. While none of the compounds C6–C9
showed appreciable activity at hFFA2 (Fig. 1C), all were
full agonists at bFFA2, although potency in this case
significantly decreased with each additional carbon
(P0.05), as chain length increased beyond C6 (Fig.
1D). Analysis of the potencies across the complete
series of n-fatty acids at hFFA2 and bFFA2 (Table 1)
reveals clearly distinct rank orders of potency, such that
for hFFA2, C3  C2  C1  C5, and all other
compounds were without effect, while for bFFA2, C6 
C5  C4  C7  C3  C8  C2  C9, and only C1 was
without effect.
To ensure that these differences were not limited to
measurement at only a -arrestin recruitment end-
Figure 1. bFFA2 is activated by longer-chain length n-fatty
acids than the human ortholog. A–H) The ability of fatty
acids of chain length C1–C5 or C6–C9 to activate hFFA2 (A,
C, E, G) or bFFA2 (B, D, F, H) was studied in either
receptor--arrestin-2 interaction assays (A–D) or phospho-
ERK 1/2 assays (E–H). Data are presented as a percentage
of the maximal effect of C3. I, J) Comparison of pEC50
values for each fatty acid at hFFA2 and bFFA2 in -arrestin-2
recruitment (I) and phospho-ERK 1/2 assays (J).
TABLE 1. Potency values for short-chain fatty acids in various assays at human and bovine orthologs of FFA2 and FFA3
Chain length
FFA2 -arrestin-2 BRET FFA2 pERK FFA3 [35S]GTPS
Human Bovine Selectivity Human Bovine Selectivity Human Bovine Selectivity
C1 2.60  0.40 2 0.6 2 2 2 2
C2 3.00  0.12 2.69  0.11 0.31 3.50  0.08 2.16  0.10 1.34 2.12  0.34 2.36  0.34 	0.24
C3 3.29  0.10 3.46  0.07 	0.17 3.64  0.06 3.26  0.07 0.38 3.70  0.13 3.81  0.18 	0.11
C4 2.83  0.26 4.16  0.06 	1.33 2.87  0.18 4.43  0.07 	1.56 3.60  0.21 3.58  0.14 0.02
C5 2.15  0.33 4.37  0.09 	2.22 2 4.30  0.10 	2.30 4.44  0.24 3.91  0.18 0.53
C6 2 4.68  0.09 	2.68 2 5.01  0.13 	3.01 3.69  0.33 3.90  0.21 	0.21
C7 2 3.81  0.09 	1.81 2 4.31  0.12 	2.31 4.16  0.56 3.80  0.61 0.36
C8 2 3.21  0.11 	1.21 2 3.12  0.13 	1.12 2 2
C9 2 2.47  0.22 	0.47 2 2 2 2
Selectivity is measured as human pEC50 	 bovine pEC50 for each assay.
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point, equivalent studies were performed by measuring
phosphorylation of ERK 1/2, and similar results were
obtained (Fig. 1E–H). In comparing the potencies for
the complete series of n-fatty acids in -arrestin-2
recruitment (Fig. 1I) and ERK 1/2 phosphorylation
(Fig. 1J), it is clear that consistently across assays, bFFA2
preferentially responded to longer chain lengths than
did hFFA2. By contrast, human and bovine orthologs of
the closely related GPCR FFA3 displayed very similar
patterns of responsiveness for each of the C1–C9 n-fatty
acids, as assessed in a [35S]GTPS assay (chosen be-
cause either bFFA3 or hFFA3 did not generate consis-
tent responses in the -arrestin-2 or ERK 1/2 assays).
Unlike bFFA2, bFFA3 displayed no preference for
longer chain lengths (Table 1).
We have recently shown that a series of small carbox-
ylic acids (SCAs) can also act as agonists at hFFA2 (20).
Considering the marked differences among the n-fatty
acids at hFFA2 and bFFA2, we next screened these
SCAs in the -arrestin-2 interaction assay to determine
whether there were also species differences within this
series (Fig. 2). A number of the SCAs, including
3-methylbutyric acid (compound 2), cyclopropylacetic
acid (compound 8), trans-crotonic acid (compound
16), and 3-methylcrotonic acid (compound 19), each
with modest potency and/or efficacy at hFFA2 in the
-arrestin-2 interaction assay were 
10- to 100-fold
more potent at bFFA2 (Fig. 3A–D). This was, however,
not a general reflection that all SCAs were more potent
at the bovine ortholog, as propiolic acid (compound
14) and angelic acid (compound 21), although display-
ing modest efficacy, were both more potent at hFFA2
than bFFA2 (Fig. 3E, F). SAR analyses of these results
with the SCAs suggest that in addition to its preference
for longer-chain fatty acids, bFFA2 also prefers com-
pounds with sp2 hybridization of the  carbon and
those with -carbon substituents.
On the basis of these SAR observations, we selected a
further set of SCAs predicted to have good selectivity
for bFFA2 because they contained longer chain lengths
(C5 or C6), sp2 hybridization of the -carbon, or bulky
substitutions at the -carbon (Table 2). Within this
series, all compounds were found to be full agonists at
bFFA2, while none possessed substantial activity at the
human receptor. In particular, it was the C5 and C6
compounds with conjugated double-bond systems that
displayed the highest potency at bFFA2. These com-
pounds included trans-2-pentenoic acid (compound 22;
Fig. 4A), trans-2-hexenoic acid (compound 23; Fig. 4B),
2,4-pentadienoic acid (compound 24; Fig. 4C), and
2,4-hexadienoic acid (sorbic acid; compound 25; Fig.
4D). Although some compounds in this series did
display weak activity at the human receptor (com-
pounds 22 and 24), all those tested that contained
larger -carbon substituents appeared to be essentially
inactive at hFFA2. These included 4,4,4-trifluoro-3-
methyl-2-butenoic acid (compound 26; Fig. 4E), 1-cy-
clopentenecarboxylic acid (compound 27; Fig. 4F),
trans-cinnamic acid (compound 28; Fig. 4G), and 1-cy-
clohexene-1-carboxylic acid (compound 29; Fig. 4H).
In addition, each of these bFFA2-selective ligands was
also inactive at the closely related hFFA3 receptor (data
not shown).
Having now identified several ligands with very good
selectivity for bFFA2 over hFFA2, we next set out to
define the molecular basis for this selectivity. In previ-
ous studies on hFFA2, sequence alignment with the
other members of the free fatty acid receptor family,
FFA1 and FFA3, identified 4 key positively charged
amino acids within the transmembrane domains. These
were arginine residues at positions 5.39 and 7.35 and
histidine residues at positions 4.56 and 6.55 (number-
ing according to the system introduced by Ballesteros
and Weinstein; ref. 24) and subsequent mutagenesis
demonstrated the importance of particularly R5.39,
R7.35, and H6.55 in coordination of the carboxylate
group of the SCFAs (19, 21). Alignment of hFFA2 and
bFFA2 indicated the presence of equivalent residues in
the bovine ortholog. However, in addition to R7.35, the
bovine ortholog has an additional arginine at position
7.36, (i.e., the next amino acid in the primary se-
quence). Each of these residues in bFFA2 was mutated
to alanine, and the resulting mutants were screened
using the -arrestin-2 interaction assay to determine
what role (if any) these residues had in the selectivity
among the identified bFFA2 ligands. The four com-
pounds that were selected for this screen were the most
prevalent SCFAs C2 and C3, and the bovine-selective
compounds C5 and 19, selected as being the most
potent bovine-selective ligands that still had apprecia-
ble activity at the human receptor (Fig. 5A; see Supple-
mental Table S1 for complete mutant screen data).
Mutation of R5.39 to alanine resulted in virtual com-
plete loss of function for all four compounds at both
the human and bovine forms of FFA2 (Fig. 5B). Inter-
estingly, although mutation to generate R7.35A in
hFFA2 resulted in complete loss of activity to each
ligand, the equivalent mutation in bFFA2 retained
some activity to the bovine-selective ligands C5 and 19,
although with 100-fold loss of potency (Fig. 5C).
Mutation of H4.56 to alanine in either hFFA2 or bFFA2
completely eliminated function (Fig. 5D), while the
H6.55 to alanine mutant retained some activity only in
bFFA2 to C5 and 19 (Fig. 5E). Mutation of the addi-
tional arginine residue present only in bFFA2 to gen-
erate R7.36A resulted in large reductions in both
efficacy and potency, although the rank-order of po-
tency of 19 C5 C3 C2 was preserved (Fig. 5F). To
assess the combined role of the two adjacent arginine
residues in bFFA2, a double R7.35A/R7.36A mutant
was generated, and this essentially failed to respond to
any ligand tested (Fig. 5G).
To identify residues in bFFA2 that may provide the
basis for its greater chain length acceptance and dis-
tinct SCA SAR, we aligned the sequence of human,
bovine, rat, and murine forms of FFA2 (Fig. 6A) and
generated a homology model of bFFA2 (Fig. 6B) based
on our previous models of the human receptor (20,
21). Nonconserved residues predicted to lie within 8 Å
of R5.39 and R7.35 of the orthosteric binding site were
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highlighted (Fig. 6B). Two of these, human S3.34/
bovine G3.34 and human C4.57/bovine G4.57, were
selected for mutational analysis. Alteration to generate
either human S3.34G or the reciprocal bovine G3.34S
forms of FFA2 had limited effects on ligand pharma-
cology, with each mutant exhibiting the same rank
order of potency for the four ligands tested as the
corresponding wild-type receptor (Fig. 6C). By contrast,
mutation to produce hFFA2-C4.57G produced a recep-
tor where although C2 and C3 remained equipotent,
the potency of C5 was increased markedly and became
significantly (P0.01) more potent than either C2 or
Figure 2. SCA concentration-response curve fit parameters in -arrestin-2 BRET at hFFA2 and bFFA2. Selectivity is expressed
as hFFA2 pEC50 	 bFFA2 pEC50. Emax values are reported as a percentage of C3 maximum response at the cognate receptor.
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C3 (Fig. 6D). Equally, compound 19 was also now
substantially more potent than C2 or C3 at this mutant
(P0.01) and, as at wild-type bFFA2, was also more
potent than C5. To confirm that this observation was
not restricted to only the -arrestin-2 interaction assay,
hFFA2-C4.57G was also assessed in ERK 1/2 phosphor-
ylation assays, and similar results were obtained (Fig.
6E). The reciprocal mutation G4.57C was also gener-
ated in bFFA2 (Fig. 6D), and although it did appear
that both C5 and 19 had reduced potency relative to C2
and C3, this was difficult to assess accurately, as this
variant receptor displayed substantially reduced effi-
cacy in the -arrestin-2 interaction assay. Therefore, to
confirm this observation, bFFA2-G4.57C was also tested
in the ERK 1/2 phosphorylation assay, which demon-
strated that it did, indeed, lose potency for the bovine-
selective compounds C5 and 19 relative to C2 and C3
(Fig. 6E).
On the basis of the gain in function we observed for
bovine-selective ligands C5 and 19 at hFFA2-C4.57G, we
next assessed whether the additional SCFAs and bovine-
selective SCAs would also activate this mutant receptor
using the -arrestin-2 interaction assay (Fig. 7 and
Table 3). Indeed, C6 and C7 were effective agonists at
this variant and now displayed potency akin to that at
the bovine ortholog (Fig. 7A, B). Among the SCAs,
particularly compounds with C6 chain lengths, such as
compounds 23 and 25, displayed dramatic gain of
function at this mutant (Fig. 7C, D), and indeed, these
compounds had equivalent activity at hFFA2-C4.57G, as
they do at the bovine receptor. In contrast, although
the series of -carbon-substituted carboxylic acids, in-
cluding, for example, compounds 26 and 29, also
gained function at the C4.57G mutant (Fig. 7E, F),
these compounds were substantially less potent at
hFFA2-C4.57G than at bFFA2, suggesting that addi-
tional residues besides 4.57 are likely to contribute to
this aspect of the bFFA2 ligand SAR.
Figure 3. A number of SCAs display marked selectivity for bFFA2. Ability of the noted compounds to promote -arrestin-2
recruitment at either hFFA2 or bFFA2 is displayed as a percentage of maximally effective concentration of C3 at each species
ortholog.
TABLE 2. Concentration-response curve-fit parameters for a refined set of SCAs predicted to have high potency and selectivity for
bovine FFA2
Compound
hFFA2 bFFA2
SelectivitypEC50 Emax pEC50 Emax
22 3 5.28  0.08 91  2 2.28
23 2 5.40  0.09 104  3 3.40
24 3.5 5.00  0.06 104  2 1.50
25 2 5.37  0.09 100  3 3.37
26 2 4.89  0.06 98  2 2.89
27 2 4.96  0.07 102  3 2.96
28 2 3.76  0.09 96  6 1.76
29 2 4.22  0.06 107  4 2.22
Selectivity is expressed as bFFA2 pEC50 	 hFFA2 pEC50. Values of pEC50  2 indicate that no measureable response was obtained. Emax
values are reported as a percentage of the C3 response at bFFA2.
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The substantial gain in function at hFFA2-C4.57G for
several ligands that are inactive at wild-type hFFA2 and
hFFA3 suggested that this mutant could form the basis
of a construct to selectively probe the function of FFA2.
However, to be useful in practice, a RASSL form of
FFA2 that not only gains function to one or more
nonendogenously generated ligands but also loses re-
sponse to the endogenous ligands is required. There-
fore, we used hFFA2-C4.57G as a lead in order to
generate a true RASSL form of hFFA2. For this, we
returned to the four positively charged residues, R5.39,
R7.35, H4.56, and H6.55, previously implicated in
SCFA binding to hFFA2 (19). Although our initial
studies on the bovine ortholog of FFA2 suggested that
mutation to alanine of either R5.39 or H4.56 resulted
in a complete loss of function (Fig. 5B, D), the alanine
mutations of both R7.35 or H6.55 each retained some
activity for the most potent bovine-selective ligands
(Fig. 5C, E). Because the retained function at R7.35
appeared to result from the presence of an additional
arginine at 7.36 in the bovine receptor that is not
present in hFFA2, we focused on H6.55. Initially, a
H6.55A mutation was incorporated into hFFA2-C4.57G
(Fig. 8A). Like bovine H6.55A, this form of hFFA2 also
retained some activity to the most potent ligand at the
human C4.57G receptor, compound 25, while losing
function for the endogenous SCFA C3. However, the
potency of compound 25 remained very low at this
mutant. Several less extreme mutations were, therefore,
also assessed. Replacement by lysine resulted in com-
plete loss of function (Fig. 8B). By contrast, introduc-
tion of asparagine, which is the residue present at this
position in the related long-chain fatty acid receptor
FFA1 (25, 26) to generate hFFA2-C4.57G/H6.55N
produced a receptor with reasonable potency for
compound 25 (Fig. 8C), while losing nearly all mea-
surable activity to the endogenous SCFA ligands
C1–C5 (Fig. 8D). To examine this further, we also
generated hFFA2-C4.57G/H6.55Q due to the similar-
ity between asparagine and glutamine. This form of
hFFA2 also retained potency for compound 25,
which was somewhat improved over hFFA2-C4.57G/
H6.55N (Fig. 8E) and also showed very little response
to each of C1–C5.
Considering the better potency observed for com-
pound 25, we further examined the potential of hFFA2-
C4.57G/H6.55Q as a true RASSL form of this receptor.
For this, it was tested across multiple functional end-
points, reflective of the range of known signaling path-
ways FFA2 is able to regulate (27). To assess Gi/o
coupling, we compared the effect of C3 at wild-type
hFFA2 on inhibition of forskolin-stimulated cAMP pro-
duction (Fig. 9A) with that of compound 25 at the mutant
receptor (Fig. 9B). While C3 and C2 were able to inhibit
forskolin-stimulated cAMP production via wild-type FFA2
(pEC504.280.19 and 4.600.30, respectively), they
both had 100-fold reduced effect on the mutant recep-
tor. Strikingly, compound 25, although completely inac-
Figure 4. Selected natural and syn-
thetic compounds display marked se-
lectivity for bovine FFA2. As in Fig. 3,
ability of the noted compounds to pro-
mote -arrestin-2 recruitment at either
hFFA2 or bFFA2 is displayed as a per-
centage of maximally effective concen-
tration of C3 at each species ortholog.
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tive at the wild-type hFFA2 receptor, strongly and potently
inhibited forskolin-stimulated cAMP production via the
mutant (pEC505.830.11). To assess coupling of
hFFA2-C4.57G/H6.55Q to Gq/11 pathways, the ability of
C3 and compound 25 to stimulate Ca2 mobilization was
examined in cells expressing wild-type hFFA2 (Fig. 9C) or
hFFA2-C4.57G/H6.55Q (Fig. 9D). Although C3 and C2
produced an increase in Ca2 via wild-type hFFA2
(pEC503.210.09 and 3.010.11, respectively), C3 had
no measurable effect at the C4.57G/H6.55Q mutant,
while C2 only produced a very small effect at 10 mM. By
contrast, compound 25 again had no effect on wild-type
hFFA2 but clearly increased Ca2 via the mutant receptor
(pEC504.630.05). Comparable experiments were con-
ducted measuring ERK 1/2 phosphorylation by C3 and
compound 25 via the wild-type (Fig. 9E) and C4.57G/
H6.55Q (Fig. 9F) forms of hFFA2. Again, similar results
were obtained: C3 and C2 effectively promoted ERK
1/2 phosphorylation via the wild-type receptor
(pEC504.130.09 and 3.940.08, respectively) but had
little effect on the mutant form, while compound 25 had
no effect at the wild type but was active and potent at the
mutant form of FFA2 (pEC505.610.06). Importantly,
not only did compound 25 activate hFFA2-C4.57G/
H6.55Q in each assay, the rank order of potency for
compound 25 at this RASSL form of hFFA2 across the
various assays was similar to that for C3 and C2 at the
wild-type receptor, such that cAMP pERK 1/2 Ca2 
-arrestin-2, suggesting that the active conformation(s) of
hFFA2-C4.57G/H6.55Q induced by compound 25 are
very similar to those of the wild-type receptor occupied by
C2 or C3. To more directly test this in an unbiased
manner, we employed a DMR assay, a method that has
been used in the past to broadly measure cellular re-
sponses to GPCR activation (20, 22, 23). As in the other
assays assessed, C3 and C2 produced DMR responses at
hFFA2 (pEC504.200.11 and 3.850.12, respectively),
and compound 25 was without effect (Fig. 9E), while at
hFFA2-C4.57G/H6.55Q, compound 25 produced a good
response (pEC505.350.06), and C3 and C2 had only
small effects at the highest concentrations tested (Fig. 9F).
Finally, DMR time-course experiments were conducted
using C3 on hFFA2 (Fig. 9G) or compound 25 on
hFFA2-C4.57G/H6.55Q (Fig. 9H). The resulting DMR
responses showed very similar profiles between the two
different forms of hFFA2, further supporting the conclu-
sion that the cellular responses of hFFA2-C4.57G/H6.55Q
to compound 25 are very similar to those of the wild-type
hFFA2 to its endogenous ligands.
In the past, generation of RASSL GPCRs has often re-
sulted in increased levels of ligand-independent constitutive
activity in the RASSL receptor (16). Therefore, in addition to
confirming that the cellular response to hFFA2-C4.57G/
H6.55Q is similar to wild-type hFFA2, it is also important to
demonstrate that hFFA2-C4.57G/H6.55Q does not display
altered levels of constitutive activity. The Flp-In T-REx cells
Figure 5. Mutational analysis of the orthosteric binding pocket of bFFA2: comparisons with the human ortholog. A–E) Wild-type
(A) and X-A mutants of residues 5.39 (B), 7.35 (C), 4.56 (D), and 6.55 (E) were assessed for -arrestin-2 recruitment at hFFA2
(Ai–Ei) and bFFA2 (Aii–Eii) in response to C2, C3, C5, and compound 19. F, G) Effects of mutating R7.36 that is present only
in bFFA2 to alanine (F) and of a double (R7.35A, R7.36A) mutant (G) were also assessed.
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provide an optimal experimental system to examine this, as
they allow direct comparison of basal signaling within the
same cell line, either with or without induced receptor
expression. However, the assays used to describe the signal-
ing properties of hFFA2-C4.57G/H6.55Q, including cAMP,
Ca2, pERK, and DMR, are not well suited to measuring
ligand-independent constitutive activity; therefore, we ex-
tended our studies to measure incorporation of [35S]GTPS,
an assay that has been widely used previously to study GPCR
constitutive activity (28–29). Initially, we demonstrated that
hFFA2 activity can be measured in this assay, as C3
(pEC504.160.11) but not compound 25 stimulated
[35S]GTPS incorporation in membranes induced to ex-
press wild-type hFFA2 (Fig. 10A). Similarly, in hFFA2-
C4.57G/H6.55Q-expressing membranes, compound 25 pro-
moted incorporation of [35S]GTPS (pEC505.460.15),
while C3 produced very little response and only at high
concentrations (Fig. 10B). To examine directly ligand-inde-
pendent activity, basal [35S]GTPS incorporation was mea-
sured in membranes isolated from either hFFA2 or hFFA2-
C4.57G/H6.55Q cells in the absence or presence of
doxycycline to induce receptor expression (Fig. 10C). In
both cases, doxycycline induction resulted in a statistically
significant (P0.001) increase in [35S]GTPS incorpora-
tion. Specifically, induced expression of hFFA2 resulted in a
157 7% increase in basal [35S]GTPS incorporation, while
induced expression of hFFA2-C4.57G/H6.55Q resulted in a
similar 156  4% (P0.05) increase. These findings dem-
onstrate that wild-type hFFA2 displays constitutive activity
and that this is unaltered by the alterations to generate
hFFA2-C4.57G/H6.55Q.
DISCUSSION
By exploring differences in pharmacology between the
human and bovine orthologs of FFA2, the most dissim-
ilar species variants of this receptor that have currently
been cloned, then generating homology models and
focusing on residues within 8 Å of the predicted
ligand-binding site for endogenously produced SCFAs,
we have been able to engineer the human ortholog to
respond to a novel group of ligands. By so doing, we
have provided new insights into the binding pocket of
the human ortholog that may allow the design of novel
and more potent ligands that target FFA2, a receptor
that is a potential therapeutic target in areas including
inflammation and metabolic diseases (4, 7, 8). More-
over, the hFFA2-C4.57G/H6.55Q mutant that we gen-
erated acts as a RASSL form of this receptor because it
Figure 6. Homology modeling and mutagenesis of
bFFA2 indicate a key role for residue G4.57 in fatty
acid chain length and compound selectivity. A, B)
Species orthologs of FFA2 were aligned (A), and
homology models of hFFA2 (Bi) and bFFA2 (Bii) were
generated. Key amino acids known to play roles in the
binding of SCFAs are boxed in red; those targeted for
mutagenesis are boxed in blue. C, D) Residues at
positions 3.34 (C) and 4.57 (D) were exchanged
between the orthologs, and the ability of C2, C3, C5,
and compound 19 to promote -arrestin-2 recruit-
ment to these variants was compared to wild type. E)
hFFA2 and bFFA2 mutants with exchanged residues at
4.57 were assessed in an ERK 1/2 phosphorylation
assay. To confirm responses were receptor mediated,
C3 concentration-response studies were also carried
out in the absence of doxycycline, to confirm it had no
effect when receptor expression was not induced.
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has also lost responsiveness to endogenously produced
activators. In this regard, the current studies have similar-
ity to the production of RASSL forms of the muscarinic
acetylcholine receptors, which no longer respond with
significant potency to acetylcholine but do so instead to
the synthetic ligand clozapine N-oxide (12, 13). However,
unlike the muscarinic receptor RASSLs, where the start-
ing point to evolve the variant forms was random mu-
tagenesis (13), herein, we have taken advantage of the
SAR differences in two species orthologs of the FFA2
receptor to the n-fatty acids and SCAs. In combination
with our previous analysis of the mode of binding and
selectivity of SCAs for FFA2 vs. the closely related receptor
FFA3 (19–21), this has allowed rational design of a RASSL
based on homology modeling and sequence alignments.
By contrast, rationalization of the basis of the selective
binding of clozapine N-oxide to a muscarinic RASSL (13)
was only possible post hoc (12).
A major challenge to understanding the physiologi-
cal roles of FFA2 is the similarity of the pharmacology
of the closely related receptor FFA3, a problem that is
compounded by the fact that these two receptors are
often coexpressed (30, 31). Although limited variation
in potency of C2 between human FFA2 and FFA3 has
resulted in its use as a selective FFA2 agonist (32),
because C2 does still have activity at FFA3 and has only
low potency at FFA2, this is far from ideal. Further-
more, apart from a series of SCAs described by Schmidt
et al. (20), which, because of their small size, also have
poor potency, the only FFA2-selective ligands currently
Figure 7. Substitution of C4.57G in hFFA2 generates responses similar to the bovine ortholog. Pharmacology of hFFA2-C4.57G
was assessed in -arrestin-2 recruitment assays with a number of ligands shown earlier to display marked selectivity for bFFA2:
C6 (A), C7 (B), compound 23 (C), compound 25 (D), compound 26 (E), and compound 29 (F).
TABLE 3. Concentration-response curve parameters for bovine selective SCFAs and SCAs at wild-type and C4.57G human FFA2
Compound
FFA2-wt FFA2-C4.57G
SelectivitypEC50 Emax pEC50 Emax vs. bFFA2
a
C6 2 4.62  0.14 112  4 NS 2.62
C7 2 3.98  0.10 119  5 NS 1.98
C8 2 2.97  0.13 109  13 NS 0.97
22 3 4.48  0.15 107  7 P  0.05 1.48
23 2 5.49  0.17 109  4 NS 3.49
24 3 4.64  0.14 113  7 P  0.01 1.64
25 2 5.34  0.21 113  6 NS 3.34
26 2 3.59  0.16 96  12 P  0.01 1.59
27 2 4.08  0.09 98  5 P  0.01 2.08
28 2 3.41  0.31 93  23 P  0.01 1.41
29 2 3.80  0.20 78  11 P  0.05 1.80
Selectivity is expressed as FFA2-C4.57G pEC50 	 FFA2-wt pEC50. Values of pEC50  2 indicate that no measureable response was obtained.
Values of pEC50  3 indicate that a response was observed; however, the data did not allow for the derivation of accurate curve-fit parameters.
Emax values are reported as a percentage of the C3 response at wild-type bFF2A.
aStatistical comparison of pEC50 curve-fit data between bFFA2
and hFFA2-C4.57G. NS, not significant.
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described derive from the phenylacetamide 4-CMTB
(21, 33). Although this compound has been used to
delineate effects of FFA2 (33, 34), it clearly binds to a
site distinct from the SCFAs and acts as a positive
allosteric modulator of the action of the SCFAs, as well
as a direct agonist (21, 33). With increasing apprecia-
tion of the ability of different ligands that bind to
overlapping sites on GPCRs to generate different sig-
naling profiles, a feature that is described as either
functional selectivity (35) or ligand bias (36, 37), there
must be the possibility that agonists that bind to differ-
ent sites of a GPCR will result in such bias. This issue,
although important, remains to be explored for the
actions of 4-CMTB and related allosteric ligands at
FFA2, and thus, we wished to modify the orthosteric
binding pocket of FFA2.
Figure 8. Alterations at residue 6.55 to hFFA2-C4.57G generate a RASSL form of hFFA2. hFFA2-C4.57G was modified further
by substitution of H6.55 to alanine (A), lysine (B), asparagine (C, D) or glutamine (E, F). Action of either C3 or compound 25
was then assessed in -arrestin-2 recruitment assays. D, F) C1–C5 n-fatty acids were tested for activity.
Figure 9. RASSL behavior of hFFA2-C4.57G/H6.55Q is ob-
served in a range of signal transduction endpoints. A–H)
Activity of C2, C3, and compound 25 was assessed at hFFA2
wild type (A, C, E, G) and hFFA2-C4.57G/H6.55Q (B, D, F, H)
for their ability to inhibit forskolin-stimulated cAMP produc-
tion (A, B), elevate intracellular Ca2 (C, D), increase phos-
pho-ERK 1/2 (E, F) and affect DMR (G, H). I, J) DMR time
course experiments are shown for hFFA2 with compound C3
(I) and for hFFA2-C4.57G/H6.55Q with compound 25 (J).
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An important secondary finding of this work is our
demonstration that the pharmacology of bFFA2 is
significantly different from that of hFFA2. Although
previous work had cloned the bovine SCFA receptors
FFA2 and FFA3 (38), little was known about their
pharmacology. Our demonstration that bFFA2 re-
sponds with a completely different rank order of po-
tency to the SCFAs than does hFFA2 suggests that this
receptor may serve different functions in bovines com-
pared with humans, and, clearly, future studies on
bFFA2 should take into account its unique ligand
selectivity. The bovine ortholog of FFA2 was chosen for
this study based on the hypothesis that species, includ-
ing ruminants, that rely heavily on nondigestible car-
bohydrates are exposed to significantly higher SCFA
concentrations (39) and, therefore, were most likely to
have SCFA receptors with distinct pharmacology. Al-
though our findings with bFFA2 appear to support this
conclusion, it is also important to consider whether this
pharmacology may be preserved in other species with
high dietary levels of nondigestible carbohydrates. An
alignment of species orthologs of FFA2 (Supplemental
Fig. S1) reveals that the only other species with glycine
at position 4.57, and, therefore, likely to display similar
pharmacology to bFFA2, is the goat, the only other
ruminant for which sequencing data are available.
Interestingly, the second unique residue that appears
to contribute to the pharmacology of bFFA2, R7.36, is
also conserved in goat FFA2, indicating that the phar-
macology of goat FFA2 is likely to be very similar to
bFFA2. Interestingly, the horse ortholog of FFA2 does
not appear likely to share pharmacology with bFFA2 on
the basis of this sequence alignment (Supplemental
Fig. S1), this despite the fact that the horse is also
heavily reliant on nondigestible carbohydrates, and, in
fact, shows SCFAs concentrations in the digestive tract
similar to those observed in ruminants (39). Therefore,
it appears that the unique pharmacology of bFFA2 is
likely restricted to ruminants and may be related to the
fact that FFA2 is expressed in the rumen of these
animals (38, 40). Indeed, it is conceivable that the two
primary changes that we describe in the pharmacology
of bFFA2, namely, a loss of potency to C2 and gain of
function to longer chain lengths, may be an evolution-
ary adaptation designed to maintain dynamic FFA2
function in the high-SCFA-concentration environment
of the rumen, where C2, as the predominant SCFA, is
present in very high concentrations, but lower levels of
longer-chain compounds are also observed (39).
Our initial studies, demonstrating the unique phar-
macology of bFFA2, precipitated efforts to understand
the molecular basis for this finding. Despite the avail-
ability of atomic level structure of a number of GPCRs
(41–43), homology modeling remains challenging.
This is particularly true for receptors with limited
sequence homology to GPCRs of known structure.
However, both because the binding sites for fatty acids
in FFA1 (25, 26, 44), FFA2 (19), and FFA3 (19) have
been explored by mutagenesis and our homology
model of FFA1 has been validated by its use in “virtual
screening” to identify novel ligands at FFA1 (26), we
have been able to model and compare hFFA2 and
bFFA2 with some confidence. The models indicated
two residues that differ between hFFA2 and bFFA2 that
are in proximity to arginine residues, two in the human
(5.39 and 7.35), and as we now show, three in the
bovine (5.39, 7.35, and 7.36) that coordinate the car-
boxylate group of the fatty acid ligands. These were,
therefore, potential candidates to underpin the species
chain-length selectivity. While alteration of position
3.34 in hFFA2 to the bovine sequence had little effect
on pharmacology, alteration of the cysteine at position
4.57 in hFFA2 to glycine, which is present in this
¹position of bFFA2, was sufficient to markedly en-
hance potency to the longer-chain SCFAs C5–C8, as
well as to a number of SCAs that we showed to be
markedly selective for bFFA2 over hFFA2. To gener-
ate a more useful RASSL form of hFFA2, it was also
important to develop a receptor that no longer
responded to its endogenous SCFA ligands. We
achieved this through the addition of a second
mutation H6.55Q, one of the positively charged
residues previously shown to play a role in SCFA
ligand binding (19). Overall, our development of this
RASSL form of hFFA2 represents a novel, more
rational, approach to chemically engineering ligand
Figure 10. Wild-type hFFA2 and hFFA2-C4.57G/H6.55Q display similar levels of ligand-independent constitutive activity. A, B)
Ability of C3 and compound 25 to stimulate [35S]GTPS incorporation was assessed in membranes expressing either hFFA2 (A)
or hFFA2-C4.57G/H6.55Q (B). C) Basal levels of [35S]GTPS incorporation were measured in membranes harvested from cells
that were either untreated or stimulated with doxycycline (Dox; 100 ng/ml) to induce expression of either hFFA2 or
hFFA2-C4.57G/H6.55Q.
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selectivity at a GPCR based on pharmacological dif-
ferences between species. This is in contrast to
approaches based on random mutagenesis and di-
rected molecular evolution used to develop RASSL
forms of the muscarinic receptors (13). However, a
combination of these two approaches, whereby spe-
cies differences could be used to rationally identify a
RASSL “lead,” followed by subsequent molecular
evolution to mature an ideal RASSL ligand binding
site, may well represent an approach to generate
RASSLs with even more favorable properties in the
future.
In addition to modifying the RASSL receptor to alter
its pharmacology, the selection of an ideal ligand to
activate the RASSL is also of critical importance. The
ligand chosen to activate the hFFA2-RASSL described
here, compound 25, is a natural compound that is
widely used as an antifungal preservative in various
foodstuffs (45). The compound is essentially nontoxic,
with a reported LD50 in rodents of 8–10 g/kg (46),
suggesting that it could be used in vivo without signifi-
cant side effects. At present, little is known about the
bioavailability or tissue distribution of compound 25,
and future work will need to address these issues.
Interestingly, the compound is approved for use as an
additive to cattle feed, and although at least one study
has suggested that its use does not affect cattle weight
gain (47), future work may well consider what biologi-
cal effects its use in this context might have, given its
ability to activate bFFA2.
Similar RASSLs of muscarinic acetylcholine receptor
subtypes have been used to produce transgenic ani-
mals to selectively study the functions of individual
muscarinic subtypes in a variety of both ex vivo and in
vivo assays (14, 15). Our demonstration that com-
pound 25 has similar signaling properties at the
hFFA2-RASSL to those of C3 at the wild receptor
across multiple assays indicates that this hFFA2-
RASSL would be ideal for these types of studies using
knock-in transgenesis. In addition to their use differ-
entiating the actions of closely related GPCRs,
RASSLs have also been used as a means to explore
selective activation of individual signaling pathways
in cells or tissues that have been engineered to
express the RASSL (16). Although there are RASSLs
described previously for each of the three primary
G signaling pathways (Gs, Gi, and Gq), the hFFA2-
RASSL described in the present work is the first
RASSL to selectively coactivate two of these pathways,
and thus may represent a novel means to explore
combined Gi/Gq activation after its expression in
vitro or in vivo. Furthermore, RASSLs have generated
recent interest for their potential use as molecular
switches in engineered tissues that could ultimately
be used therapeutically in humans (16). The FFA2
RASSL described in the current work may be of
particular interest in this respect, given that its ligand
is nontoxic and, indeed, already approved for human
consumption. Taken together, in the present work,
we have described a novel approach to developing
chemically engineered GPCRs based on the pharma-
cological variation between species orthologs, and in
doing so, have developed a valuable reagent for the
future study of FFA2 function.
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